DE69617273D1 - Heterocyclisch substituierte cyclopentanderivate. - Google Patents
Heterocyclisch substituierte cyclopentanderivate.Info
- Publication number
- DE69617273D1 DE69617273D1 DE69617273T DE69617273T DE69617273D1 DE 69617273 D1 DE69617273 D1 DE 69617273D1 DE 69617273 T DE69617273 T DE 69617273T DE 69617273 T DE69617273 T DE 69617273T DE 69617273 D1 DE69617273 D1 DE 69617273D1
- Authority
- DE
- Germany
- Prior art keywords
- substituted cyclopentane
- heterocyclically substituted
- cyclopentane derivatives
- compounds
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical class C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 title 1
- OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 abstract 2
- 108010076278 Adenosine kinase Proteins 0.000 abstract 2
- 102100032534 Adenosine kinase Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 125000001511 cyclopentyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47248695A | 1995-06-07 | 1995-06-07 | |
US08/651,882 US6143749A (en) | 1995-06-07 | 1996-06-04 | Heterocyclic substituted cyclopentane compounds |
PCT/US1996/009042 WO1996040686A1 (en) | 1995-06-07 | 1996-06-06 | Heterocyclic substituted cyclopentane compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69617273D1 true DE69617273D1 (de) | 2002-01-03 |
DE69617273T2 DE69617273T2 (de) | 2002-07-25 |
Family
ID=27043790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69617273T Expired - Fee Related DE69617273T2 (de) | 1995-06-07 | 1996-06-06 | Heterocyclisch substituierte cyclopentanderivate. |
Country Status (11)
Country | Link |
---|---|
US (1) | US6143749A (de) |
EP (1) | EP0873340B1 (de) |
JP (1) | JP2000501694A (de) |
AT (1) | ATE209206T1 (de) |
CA (1) | CA2220006A1 (de) |
DE (1) | DE69617273T2 (de) |
DK (1) | DK0873340T3 (de) |
ES (1) | ES2168479T3 (de) |
MX (1) | MX9709718A (de) |
PT (1) | PT873340E (de) |
WO (1) | WO1996040686A1 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721356A (en) * | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
US5674998A (en) * | 1989-09-15 | 1997-10-07 | Gensia Inc. | C-4' modified adenosine kinase inhibitors |
CH690773A5 (de) * | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
GB9704948D0 (en) | 1997-03-11 | 1997-04-30 | Knoll Ag | Therapeutic agents |
US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
KR20000076426A (ko) * | 1997-03-19 | 2000-12-26 | 스타르크, 카르크 | 피롤로[2,3-d]피리미딘 및 티로신 키나제 저해제로서의 그의 용도 |
AU7108398A (en) * | 1997-04-16 | 1998-11-11 | Abbott Laboratories | 5,7-disubstituted 4-aminopyrido{2,3-d}pyrimidine compounds and their use as adenosine kinase inhibitors |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
NZ510588A (en) * | 1998-09-18 | 2003-08-29 | Abbott Gmbh & Co | Pyrrolopyrimidines as protein kinase inhibitors |
TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
US7071199B1 (en) | 1999-09-17 | 2006-07-04 | Abbott Gmbh & Cco. Kg | Kinase inhibitors as therapeutic agents |
AU2000240570A1 (en) * | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
GB0128885D0 (en) * | 2001-12-03 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
WO2005044835A1 (en) * | 2003-10-27 | 2005-05-19 | Genelabs Technologies, Inc. | METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES |
US7345034B2 (en) * | 2004-04-07 | 2008-03-18 | Abbott Laboratories | Azacyclosteroid histamine-3 receptor ligands |
GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
TW200738725A (en) * | 2006-01-25 | 2007-10-16 | Osi Pharm Inc | Unsaturated mTOR inhibitors |
PL2013211T3 (pl) * | 2006-04-21 | 2012-08-31 | Novartis Ag | Pochodne puryny do zastosowania jako agoniści receptora adenozyny A2A |
WO2009065406A2 (en) * | 2007-11-23 | 2009-05-28 | Leo Pharma A/S | Novel cyclic hydrocarbon compounds for the treatment of diseases |
GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
CN103889983B (zh) | 2011-09-14 | 2015-12-09 | 普罗克西梅根有限公司 | 酶抑制剂化合物 |
GB201115853D0 (en) * | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
US9682083B2 (en) | 2013-05-14 | 2017-06-20 | Nerviano Medical Sciences S.R.L. | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
TWI791251B (zh) | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
MA41559A (fr) | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | Composé de pyrimidine condensé ou un sel de celui-ci |
ME03669B (de) | 2016-02-23 | 2020-10-20 | Taiho Pharmaceutical Co Ltd | Neuartige kondensierte pyrimidinverbindung oder salz davon |
JP6909799B2 (ja) | 2016-03-10 | 2021-07-28 | ヤンセン ファーマシューティカ エヌ.ベー. | Prmt5阻害剤として使用するための置換ヌクレオシドアナログ |
CA2969295A1 (en) * | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
WO2018050684A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
DK3512857T3 (da) | 2016-09-14 | 2021-05-10 | Janssen Pharmaceutica Nv | Spiro-bicykliske inhibitorer af menin-mll-interaktion |
WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
PE20190706A1 (es) * | 2016-10-03 | 2019-05-17 | Janssen Pharmaceutica Nv | Analogos novedosos de carbanucleosidos sustituidos de sistema anular monociclico y bicicilo para su uso como inhibidores de prmt5 |
US10745409B2 (en) | 2016-12-15 | 2020-08-18 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-MLL interaction |
AU2018225312B2 (en) | 2017-02-27 | 2024-02-08 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor |
WO2018160824A1 (en) * | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
IL275129B2 (en) * | 2017-12-08 | 2023-10-01 | Janssen Pharmaceutica Nv | New spirobicyclic analogs |
US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
WO2020198323A1 (en) * | 2019-03-25 | 2020-10-01 | California Institute Of Technology | Prmt5 inhibitors and uses thereof |
TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用prmt5抑制劑治療癌症之方法 |
BR112021024457A2 (pt) | 2019-06-12 | 2022-01-18 | Janssen Pharmaceutica Nv | Intermediários espirobicíclicos |
CN111320634A (zh) * | 2020-04-14 | 2020-06-23 | 浙江工业大学 | 一种乙酰氧取代的吡咯并[2,3-d]嘧啶衍生物的制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3551428A (en) * | 1956-02-10 | 1970-12-29 | Ciba Geigy Corp | New 1- (or 2-) substituted 4-mercapto-pyrazolo(3,4-d)pyrimidines |
US3296261A (en) * | 1965-03-09 | 1967-01-03 | Bristol Myers Co | 6-hydroxy-pyrimidine-5-acetamides |
US3311628A (en) * | 1965-03-09 | 1967-03-28 | Bristol Myers Co | Derivatives of pyrrolo [2, 3-d] pyrimidine |
US5378825A (en) * | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
US5223618A (en) * | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
CA2100863A1 (en) * | 1991-01-23 | 1992-07-24 | David A. Bullough | Adenosine kinase inhibitors |
EP0521463A3 (en) * | 1991-07-04 | 1993-04-14 | Hoechst Aktiengesellschaft | Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents |
WO1994006438A1 (en) * | 1992-09-11 | 1994-03-31 | The Regents Of The University Of California | Adenosine analogues and method of increasing adenosine release |
JP2895961B2 (ja) * | 1992-12-17 | 1999-05-31 | フアイザー・インコーポレイテツド | Crfアンタゴニストとしてのピロロピリミジン |
WO1994018215A1 (en) * | 1993-02-03 | 1994-08-18 | Gensia, Inc. | Adenosine kinase inhibitors comprising lyxofuranosyl derivatives |
IL108523A0 (en) * | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
-
1996
- 1996-06-04 US US08/651,882 patent/US6143749A/en not_active Expired - Fee Related
- 1996-06-06 DK DK96918151T patent/DK0873340T3/da active
- 1996-06-06 JP JP9501456A patent/JP2000501694A/ja active Pending
- 1996-06-06 PT PT96918151T patent/PT873340E/pt unknown
- 1996-06-06 ES ES96918151T patent/ES2168479T3/es not_active Expired - Lifetime
- 1996-06-06 EP EP96918151A patent/EP0873340B1/de not_active Expired - Lifetime
- 1996-06-06 WO PCT/US1996/009042 patent/WO1996040686A1/en active IP Right Grant
- 1996-06-06 CA CA002220006A patent/CA2220006A1/en not_active Abandoned
- 1996-06-06 DE DE69617273T patent/DE69617273T2/de not_active Expired - Fee Related
- 1996-06-06 AT AT96918151T patent/ATE209206T1/de not_active IP Right Cessation
-
1997
- 1997-12-05 MX MX9709718A patent/MX9709718A/es unknown
Also Published As
Publication number | Publication date |
---|---|
DE69617273T2 (de) | 2002-07-25 |
WO1996040686A1 (en) | 1996-12-19 |
EP0873340A1 (de) | 1998-10-28 |
ES2168479T3 (es) | 2002-06-16 |
JP2000501694A (ja) | 2000-02-15 |
MX9709718A (es) | 1998-07-31 |
ATE209206T1 (de) | 2001-12-15 |
DK0873340T3 (da) | 2002-05-21 |
PT873340E (pt) | 2002-05-31 |
EP0873340B1 (de) | 2001-11-21 |
CA2220006A1 (en) | 1996-12-19 |
US6143749A (en) | 2000-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69617273D1 (de) | Heterocyclisch substituierte cyclopentanderivate. | |
ATE267200T1 (de) | Bicyclische kinase inhibitoren | |
ATE292118T1 (de) | Pyrazolderivative als p-38 map kinase inhibitoren | |
DK0693073T3 (da) | Bicykliske ansamyciner og deres anvendelse som antitumormidler | |
MX9707431A (es) | Inhibidores de la proteina cinasa c. | |
TR199900049T2 (xx) | Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler. | |
TR199800759T2 (xx) | Protein Kinaz C �nhibit�r�. | |
AR021811A1 (es) | Compuestos de piridina fusionados, utiles como inhibidores de gmpc fosfodiesterasa y las composiciones farmaceuticas que las contienen. | |
ES2162843T3 (es) | Inhibidores de la proteina quinasa c. | |
ES2175624T3 (es) | Derivados de pirazolo(4,3-d)pirimidina y composiciones farmaceuticas que los contienen. | |
DE69620161T2 (de) | Thrombininhibitoren | |
AR024138A1 (es) | Inhibidores de la proliferacion celular | |
DE60112742D1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
GEP20084346B (en) | Protein kinase c inhibitors | |
ATE293964T1 (de) | Zusammensetzungen und verfahren zur behinderung der entladung von nematokyste | |
MX9203241A (es) | Derivados de indol y composiciones farmaceuticas que los contienen. | |
AR028186A1 (es) | Compuestos de 5-aril-1, 2, 4-triazol inhibidores de ciclooxigenasa-2 y composiciones farmaceuticas que comprenden dichos compuestos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |